Fragment-based identification of amides derived from trans-2-(pyridin-3-yl) cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT)

Journal of Medicinal Chemistry

Volumn 57, Issue 3, 2014, Pages 770-792

  Giannetti, Anthony M ^a   Zheng, Xiaozhang ^b   Skelton, Nicholas J ^a   Wang, Weiru ^a   Bravo, Brandon J ^a   Bair, Kenneth W ^b   Baumeister, Timm ^b   Cheng, Eric ^a   Crocker, Lisa ^a   Feng, Yezhen ^c   Gunzner Toste, Janet ^a   Ho, Yen Ching ^b   Hua, Rongbao ^c   Liederer, Bianca M ^a   Liu, Yongbo ^c   Ma, Xiaolei ^a   O'Brien, Thomas ^a   Oeh, Jason ^a   Sampath, Deepak ^a   Shen, Youming ^c   Wang, Chengcheng ^d   Wang, Leslie ^a   Wu, Hongxing ^c   Xiao, Yang ^a   Yuen, Po Wai ^c   Zak, Mark ^a   Zhao, Guiling ^a   Zhao, Qiang ^d   Dragovich, Peter S ^a   more..

^a GENENTECH INC   (United States)

^b Forma Therapeutics   (United States)

^c Pharmaron Beijing Co Ltd   (China)

^d Science and Technology Innovation Park   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMIDES; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CRYSTALLOGRAPHY, X-RAY; CYCLOPROPANES; DRUG SCREENING ASSAYS, ANTITUMOR; HETEROGRAFTS; HUMANS; MICE; MICE, NUDE; MODELS, MOLECULAR; NEOPLASM TRANSPLANTATION; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PROTEIN CONFORMATION; PYRIDINES; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONES;

EID: 84894102697     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm4015108     Document Type: Article

References (73)

1. + metabolism in health and disease Trends Biochem. Sci. 2007, 32, 12-19
2. +: an old metabolite controlling new metabolic signaling pathways Endocr. Rev. 2010, 31, 194-223
3. 3: from metabolism to therapies J. Pharmacol. Exp. Ther. 2008, 324, 883-893
4. Mammalian cells can also efficiently synthesize NAD from nicotinic acid (niacin) via the Preiss-Handler pathway: Preiss, J.; Handler, P. Biosynthesis of diphosphopyridine nucleotide. I. Identification of intermediates J. Biol. Chem. 1958, 233, 488-492
5. Burgos, E. S. NAMPT in regulated NAD biosynthesis and its pivotal role in human metabolism Curr. Med. Chem. 2011, 18, 1947-1961
6. Dahl, T. B.; Holm, S.; Aukrust, P.; Halvorsen, B. Visfatin/NAMPT: a multifaceted molecule with diverse roles in physiology and pathophysiology Annu. Rev. Nutr. 2012, 32, 229-243
7. Burgos, E. S.; Ho, M.-C.; Almo, S. C.; Schramm, V. L. A phosphoenzyme mimic, overlapping catalytic sites and reaction coordinate motion for human NAMPT Proc. Natl. Acad. Sci. U.S.A. 2009, 106, 13748-13753
8. Kim, M.-K.; Lee, J. H.; Kim, H.; Park, S. J.; Kim, S. H.; Kang, G. B.; Lee, Y. S.; Kim, J. B.; Kim, K. K.; Suh, S. W.; Eom, S. H. Crystal structure of visfatin/pre-B cell colony enhancing factor 1/nicotinamide phosphoribosyltransferase, free and in complex with the anti-cancer agent FK-866 J. Mol. Biol. 2006, 362, 66-77
9. + biosynthetic enzyme Nat. Struct. Mol. Biol. 2006, 13, 661-662
10. Khan, J. A.; Tao, X.; Tong, L. Molecular basis for the inhibition of human NMPRTase, a novel target for anticancer agents Nat. Struct. Mol. Biol. 2006, 13, 582-588
11. Burgos, E. S.; Schramm, V. L. Weak coupling of ATP hydrolysis to the chemical equilibrium of human nicotinamide phosphoribosyltransferase Biochemistry 2008, 47, 11086-11096
12. Burgos, E. S.; Vetticatt, M. J.; Schramm, V. L. Recycling nicotinamide. The transition-state structure of human nicotinamide phosphoribosyltransferase J. Am. Chem. Soc. 2013, 135, 3485-3493
13. Schulze, A.; Harris, A. L. How cancer metabolism is tuned for proliferation and vulnerable to disruption Nature 2012, 491, 364-373
14. Ward, P. S.; Thompson, C. B. Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate Cancer Cell 2012, 21, 297-308
15. Jones, N. P.; Schulze, A. Tagreting cancer metabolism-aiming at a tumor's sweet spot Drug Discovery Today 2012, 17, 232-241
16. Tennant, D. A.; Durán, R. V.; Gottlieb, E. Targeting metabolic transformation for cancer therapy Nat. Rev. Cancer 2010, 10, 267-277
17. Cerna, D.; Li, H.; Flaherty, S.; Takebe, N.; Coleman, C. N.; Yoo, S. S. Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) activity by the small molecule GMX1778 regulates ROS-mediated cytotoxicity in a p53- and nicotinic acid phosphoribosyltransferase1 (NAPRT1)-dependent manner J. Biol. Chem. 2012, 287, 22408-22417
18. Vander Heiden, M. G.; Cantley, L. C.; Thompson, C. B. Understanding the Warburg effect: the metabolic requirements of cell proliferation Science 2009, 324, 1029-1033
19. Chiarugi, A.; Dölle, C.; Felici, R.; Ziegler, M. The NAD metabolome-a key determinant of cancer cell biology Nat. Rev. Cancer 2012, 12, 741-752
20. He, J.; Tu, C.; Li, M.; Wang, S.; Guan, X.; Lin, J.; Li, Z. Nampt/visfatin/PBEF: a functionally multi-faceted protein with a pivotal role in malignant tumors Curr. Pharm. Des. 2012, 18, 6123-6132
21. Garten, A.; Petzold, S.; Körner, A.; Imai, S.-i.; Kiess, W. Nampt: linking NAD biology, metabolism and cancer Trends Endocrinol. Metab. 2008, 20, 130-138
22. Khan, J. A.; Forouhar, F.; Tao, X.; Tong, L. Nicotinamide adenine dinucleotide metabolism as an attractive target for drug discovery Expert Opin. Ther. Targets 2007, 11, 695-705
23. Schou, C.; Ottosen, E. R.; Petersen, H. J.; Bjorkling, F.; Latini, S.; Hjarnaa, P. V.; Bramm, E.; Binderup, L. Novel cyanoguanidines with potent oral antitumor activity Bioorg. Med. Chem. Lett. 1997, 7, 3095-3100
24. Olesen, U. H.; Christensen, M. K.; Björkling, F.; Jäättelä, M.; Jensen, P. B.; Sehested, M.; Nielsen, S. J. Anticancer agent CHS-828 inhibits cellular synthesis of NAD Biochem. Biophys. Res. Commun. 2008, 367, 799-804
25. + biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-deficient tumors Mol. Cell. Biol. 2009, 29, 5872-5888
26. Hasmann, M.; Schemainda, I. FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis Cancer Res. 2003, 63, 7436-7442
27. Wosikowski, K.; Mattern, K.; Schemainda, I.; Hasmann, M.; Rattel, B.; Löser, R. WK175, a novel antitumor agent, decreases the intracellular nicotinamide adenine dinucleotide concentration and induces the apoptotic cascade in human leukemia cells Cancer Res. 2002, 62, 1057-1062
28. Ravaud, A.; Cerny, T.; Terret, C.; Wanders, J.; Bui, B. N.; Hess, D.; Droz, J.-P.; Fumoleau, P.; Twelves, C. Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: an ECSG/EORTC study Eur. J. Cancer. 2005, 41, 702-707
29. Hovstadium, P.; Larsson, R.; Jonsson, E.; Skov, T.; Kissmeyer, A.-M.; Krasilnikoff, K.; Bergh, J.; Karlsson, M. O.; Lonnebo, A.; Ahlgren, J. A phase I study of CHS 828 in patients with solid tumor malignancy Clin. Cancer Res. 2002, 8, 2843-2850
30. Binderup, E.; Bjorkling, F.; Hjarnaa, P. V.; Latini, S.; Baltzer, B.; Carlsen, M.; Binderup, L. EB1627: a soluble prodrug of the potent anticancer cyanoguanidine CHS828 Bioorg. Med. Chem. Lett. 2005, 15, 2491-2494
31. Beauparlant, P.; Bédard, D.; Bernier, C.; Chan, H.; Gilbert, K.; Goulet, D.; Gratton, M.-O.; Lavoie, M.; Roulston, A.; Turcotte, E.; Watson, M. Preclinical development of the nicotinamide phosphoribosyl transferase inhibitor prodrug GMX1777 Anti-Cancer Drugs 2009, 20, 346-354
32. Pishvaian, M. J.; Marshall, J. L.; Hwang, J. H.; Malik, S. M.; He, A. R.; Deeken, J. F.; Kelso, C. B.; Dorsch-Vogel, K.; Berger, M. S. A phase 1 trial of GMX1777: an inhibitor of nicotinamide phosphoribosyltransferase (NAMPRT) J. Clin. Oncol. 2008, 26 (Suppl.) 14568
33. Pishvaian, M. J.; Marshall, J. L.; Hwang, J. H.; Malik, S. M.; He, A. R.; Deeken, J. F.; Kelso, C. B.; Cotarla, I.; Berger, M. S. A phase 1 trial of GMX1777: an inhibitor of nicotinamide phosphoribosyltransferase (NAMPRT), given as a 24-h infusion J. Clin. Oncol. 2009, 27 (Suppl.) 3581
34. Holen, K.; Saltz, L. B.; Hollywood, E.; Burk, K.; Hanauske, A.-R. The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor Invest. New Drugs 2008, 26, 45-51
35. Arigon, J.; Bernhart, C.; Bouaboula, M.; Dimalta, A.; Nardi, F.; Jegham, S. Nicotinamide Derivatives, Preparation Thereof and Therapeutic Uses Thereof. WO 2012038904, 2012.
36. Arigon, J.; Bernhart, C.; Bosch, M.; Bouaboula, M.; Nardi, F.; Jegham, S.; Combet, R. Thienopyridine Nicotinamide Derivatives, Preparation Thereof and Therapeutic Use Thereof. WO 2012038905, 2012.
37. Curtin, M. L.; Sorensen, B. K.; Heyman, H. R.; Clark, R. F.; Woller, K. R.; Shah, O. J.; Michaelides, M.; Tse, C.; Vasudevan, A.; Mack, H.; Hansen, T. M.; Sweis, R.; Pliushchev, M. A. Dihydroisoindolecarboxamide Derivatives as NAMPT and ROCK Inhibitors and Their Preparation. US 20120122842, 2012.
38. Curtin, M. L.; Sorensen, B. K.; Heyman, H. R.; Clark, R. F.; Michaelides, M.; Tse, C. NAMPT Inhibitors as Therapeutic Agents for the Treatment of Diseases. US 20120122924, 2012.
39. Kumar, D. V.; Slattum, P. M.; Yager, K. M.; Shenderovich, M. D.; Tangallapally, R.; Kim, S. Compounds and Therapeutic Uses Thereof. WO 2012177782, 2012.
40. Willardsen, A. J.; Lockman, J. W.; Murphy, B. R.; Judd, W. R.; Kim, I. C.; Kim, S.-H.; Zigar, D. F.; Yager, K. M.; Fleischer, T. C.; Terry-Lorenzo, R. T.; Boniface, J. J.; Parker, D. P.; McAlexander, I. A.; Bursavich, M. G.; Dastrup, D. M. Compounds and Therapeutic Uses Thereof. WO 2011109441, 2011.
41. You, H.; Youn, H.-S.; Im, I.; Bae, M.-H.; Lee, S.-K.; Ko, H.; Eom, S. H.; Kim, Y.-C. Design, synthesis and X-ray crystallographic study of NAmPRTase inhibitors as anti-cancer agents Eur. J. Med. Chem. 2011, 46, 1153-1164
42. Arigon, J.; Bernhart, C.; Bouaboula, M.; Combet, R.; Jegham, S.; Hilairet, S. Anticancer Compounds, Preparation Thereof, and Therapeutic Use Thereof. WO 2010109115, 2010.
43. Arigon, J.; Bernhart, C.; Bouaboula, M.; Combet, R.; Hilairet, S.; Jegham, S. Nicotinamide Derivatives, Preparation Thereof and Therapeutic Use Thereof as Anticancer Drugs. WO 2010109112, 2010.
44. Lockman, J. W.; Murphy, B. R.; Zigar, D. F.; Judd, W. R.; Slattum, P. M.; Gao, Z.-H.; Ostanin, K.; Green, J.; McKinnon, R.; Terry-Lorenzo, R. T.; Fleischer, T. C.; Boniface, J. J.; Shenderovich, M.; Willardsen, J. A. Analogues of 4-[(7-bromo-2-methyl-4-oxo-3 H -quinazolin-6-yl)methylprop-2-ynylamino]- N -(3-pyridylmethyl)-benzamide (CB-30865) as potent inhibitors of nicotinamide phosphoribosyltransferase (Nampt) J. Med. Chem. 2010, 53, 8734-8746
45. Bernhart, C.; Bouaboula, M.; Casellas, P.; Jegham, S.; Arigon, J.; Combet, R.; Hilairet, S.; Fraisse, P. Nicotinamide Derivatives, Preparation Thereof and Therapeutic Use Thereof. US 20100222319, 2010.
46. Bernhart, C.; Bouaboula, M.; Casellas, P.; Duclos, O.; Bernhart, J. M.; Jegham, S.; McCort, G. Antineoplastic Derivatives, Preparation Thereof, and Therapeutic Use Thereof. WO 2010004198, 2010.
47. Colombano, G.; Travelli, C.; Galli, U.; Caldarelli, A.; Chini, M. G.; Canonico, P. L.; Sorba, G.; Bifulco, G.; Tron, G. C.; Genazzani, A. A. A novel potent nicotinamide phosphoribosyltransferase inhibitor synthesized via click chemistry J. Med. Chem. 2010, 53, 616-623
48. Galli, U.; Ercolano, E.; Carraro, L.; Blasi Roman, C. R.; Sorba, G.; Canonico, P. L.; Genazzani, A. A.; Tron, G. C.; Billington, R. A. Synthesis and biological evaluation of isosteric analogues of FK866, an inhibitor of NAD salvage ChemMedChem. 2008, 3, 771-779
49. For a recent review of NAMPT and associated inhibitors, see the following: Galli, U.; Travelli, C.; Massarrotti, A.; Fakhfouri, G.; Rahimian, R.; Tron, G. C.; Genazzani, A. A. Medicinal chemistry of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors J. Med. Chem. 2013, 56, 6279-6296
50. Zheng, X.; Bauer, P.; Baumeister, T.; Buckmelter, A. J.; Caligiuri, M.; Clodfelter, K. H.; Han, B.; Ho, Y.-C.; Kley, N.; Lin, J.; Reynolds, D. J.; Sharma, G.; Smith, C. C.; Wang, Z.; Dragovich, P. S.; Oh, A.; Wang, W.; Zak, M.; Gunzner-Toste, J.; Zhao, G.; Yuen, P.-w.; Bair, K. W. Structure-based identification of ureas as novel nicotinamide phosphoribosyltransferase (Nampt) inhibitors J. Med. Chem. 2013, 56, 4921-4937
51. Gunzner-Toste, J.; Zhao, G.; Bauer, P.; Baumeister, T.; Buckmelter, A. J.; Caligiuri, M.; Clodfelter, K. H.; Fu, B.; Han, B.; Ho, Y.-C.; Kley, N.; Liang, X.; Liederer, B.; Lin, J.; Mukadam, S.; O'Brien, T.; Oh, A.; Reynolds, D. J.; Sharma, G.; Skelton, N.; Smith, C. C.; Sodhi, J.; Wang, W.; Wang, Z.; Xiao, Y.; Yuen, P.-w.; Zak, M.; Zhang, L.; Zheng, X.; Bair, K. W.; Dragovich, P. S. Discovery of potent and efficacious urea-containing nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with reduced CYP2C9 inhibition properties Bioorg. Med. Chem. Lett. 2013, 23, 3531-3538
52. Zheng, X.; Bauer, P.; Baumeister, T.; Buckmelter, A. J.; Caligiuri, M.; Clodfelter, K. H.; Han, B.; Ho, Y.-C.; Kley, N.; Lin, J.; Reynolds, D. J.; Sharma, G.; Smith, C. C.; Wang, Z.; Dragovich, P. S.; Gunzner-Toste, J.; Liederer, B.; Ly, J.; O'Brien, T.; Oh, A.; Wang, L.; Wang, W.; Xiao, Y.; Zak, M.; Zhao, G.; Yuen, P.-w.; Bair, K. W. Structure-based discovery of novel amide-containing nicotinamide phosphoribosyltransferase (Nampt) inhibitors J. Med. Chem. 2013, 56, 6413-6433
53. Dragovich, P. S.; Bair, K. W.; Baumeister, T.; Ho, Y.-C.; Liederer, B. M; Liu, X.; Liu, Y.; O'Brien, T.; Oeh, J.; Sampath, D.; Skelton, N.; Wang, L.; Wang, W.; Wu, H.; Xiao, Y.; Yuen, P.-w.; Zak, M.; Zhang, L.; Zheng, X. Identification of 2,3-dihydro-1 H -pyrrolo[3,4- c ]pyridine-derived ureas as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT) Bioorg. Med. Chem. Lett. 2013, 23, 4875-4885
54. Zheng, X.; Bair, K. W.; Bauer, P.; Baumeister, T.; Bowman, K. K.; Buckmelter, A. J.; Caligiuri, M.; Clodfelter, K. H.; Feng, Y.; Han, B.; Ho, Y.-C.; Kley, N.; Li, H.; Liang, X.; Liederer, B. M.; Lin, J.; Ly, J.; O'Brien, T.; Oeh, J.; Oh, A.; Reynolds, D. J.; Sampath, D.; Sharma, G.; Skelton, N.; Smith, C. C.; Tremayne, J.; Wang, L.; Wang, W.; Wang, Z.; Wu, H.; Wu, J.; Xiao, Y.; Yang, G.; Yuen, P.-w.; Zak, M.; Dragovich, P. S. Identification of amides derived from 1 H -pyrazolo[3,4- b ]pyridine-5-carboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT) Bioorg. Med. Chem. Lett. 2013, 23, 5488-5497
55. Kumar, A.; Voet, A.; Zhang, K. Y. J. Fragment based drug design: from experimental to computational approaches Curr. Med. Chem. 2012, 19, 5128-5147
56. de Kloe, G. e.; Bailey, D.; Leurs, R.; de Esch, I. J. P. Transforming fragments into candidates: small becomes big in medicinal chemistry Drug Discovery Today 2009, 14, 630-646
57. Congreve, M.; Chessari, G.; Tisi, D.; Woodhead, A. J. Recent developments in fragment-based drug discovery J. Med. Chem. 2008, 51, 3661-3680
58. Hopkins, A. L.; Groom, C. R.; Alex, A. Ligand efficiency: a useful metric for lead selection Drug Discovery Today 2004, 9, 430-431
59. The benzothiadiazine tautomer depicted for compound 9 in Table 1 was predicted by the software package MoKa (v1.1; Molecular Discovery) to be preferred over the alternative tautomeric form (calculated population 100%). Similar preferences were found for compounds 10 and 11. These predictions are consistent with hydrogen bonds observed crystallographically between compounds 9 and 11 and NAMPT (cf., Figures 6 and 7). For additional information regarding MoKa, see the following: Milletti, F.; Storchi, L.; Sforna, G.; Cross, S.; Cruciani, G. Tautomer enumeration and stability prediction for virtual screening on large chemical databases J. Chem. Inf. Model. 2009, 49, 68-75
60. Yeo, H. L.; Song, Y. S.; Ryu, J.-H.; Kim, H.-D. Design, synthesis, and biological evaluation of cyclopropyl analogues of stilbene with raloxifene side chain as subtypeselective ligands for estrogen receptor Arch. Pharm. Res. 2013, 36, 1096-1103
61. Lagu, B.; Lebedev, R.; Pio, B.; Yang, M.; Pelton, P. D. Dihydro-[1 H ]-quinolin-2-ones as retinoid X receptor (RXR) agonists for potential treatment of dyslipidemia Bioorg. Med. Chem. Lett. 2007, 17, 3491-3496
62. Wipf, P.; Xiao, J. Convergent approach to (E)-alkene and cyclopropane peptide isosteres Org. Lett. 2005, 7, 103-106
63. Carpita, A.; Ribecai, A.; Rossi, R.; Stabile, P. Synthesis of the racemic forms of carbon-carbon double bond locked analogues of strobilurins which are characterized by a 2-arylcyclopropane ring cis -substituted at C-1 by the methyl (E)-3-methoxypropenoate unit Tetrahedron 2002, 58, 3673-3680
64. The preparation of this material is also described in the patent literature: Bair, K. W.; Baumeister, T.; Buckmelter, A. J.; Clodfelter, K. H.; Dragovich, P.; Gosselin, F.; Han, B.; Lin, J.; Reynolds, D. J.; Roth, B.; Smith, C. C.; Wang, Z.; Yuen, P.-w.; Zheng, X. Novel Compounds and Compositions for the Inhibition of NAMPT. WO 2012031197, 2012.
65. Morisawa, Y.; Kataoka, M.; Nagahori, H.; Sakamoto, T.; Kitano, N.; Kusano, K.; Sato, K. Studies on anticoccidial agents. 13. Synthesis and anticoccidial activity of nitropyridine-2- and -3-sulfonamides and derivatives J. Med. Chem. 1980, 23, 1376-1380
66. Pirotte, B.; de Tullio, P.; Lebrun, P.; Antoine, M.-H.; Fontaine, J.; Masereel, B.; Schynts, M.; Dupont, L.; Herchuelz, A.; Delarget, J. 3-(Alkylamino)-4 H -pyrido[4,3- e ]-l,2,4-thiadiazine 1,l-dioxides as powerful inhibitors of insulin release from rat pancreatic B-cells: a new class of potassium channel openers? J. Med. Chem. 1993, 36, 3211-3213
67. Toy, P. H.; Dhanabalasingam, B.; Newcomb, M.; Hanna, I. H.; Hollenberg, P. F. A substituted hypersensitive radical probe for enzyme-catalyzed hydroxylations: synthesis of racemic and enantiomerically enriched forms and application in a cytochrome P450-catalyzed oxidation J. Org. Chem. 1997, 62, 9114-9122
68. Rodriques, K. E. A novel route to cyclopropyl ketones, aldehydes, and carboxylic acids Tetrahedron Lett. 1991, 32, 1275-1278
69. 3-receptor antagonists of the 2-aminobenzimidazole series Bioorg. Med. Chem. 2006, 14, 1413-1424
70. Gillig, A.; Majjigapu, S. R.; Sordat, B.; Vogel, P. Synthesis of a C -iminoribofuranoside analog of the nicotinamide phosphoribosyltransferase (NAMPT) inhibitor FK866 Helv. Chim. Acta 2012, 95, 34-42
71. You, H.; Youn, H.-S.; Im, I.; Bae, M.-H.; Lee, S.-K.; Ko, H.; Eom, S. H.; Kim, Y.-C. Design, synthesis and X-ray crystallographic study of NAmPRTase inhibitors as anti-cancer agents Eur. J. Med. Chem. 2011, 46, 1153-1164
72. Giannetti, A. M. From experimental design to validated hits: a comprehensive walk-through of fragment lead identification using surface plasmon resonance Methods Enzymol. 2011, 493, 169-218
73. Giannetti, A. M.; Koch, B. D.; Browner, M. F. Surface plasmon resonance based assay for the detection and characterization of promiscuous inhibitors J. Med. Chem. 2008, 51, 574-580